Rheumatology Advance Access originally published online on September 27, 2005
Rheumatology 2005 44(12):1542-1545; doi:10.1093/rheumatology/kei080
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients
Centre for Rheumatology, University College London, London, UK.
Correspondence to: D. Isenberg, Centre for Rheumatology, University College London, 4th Floor, Arthur Stanley House, 40–50 Tottenham Street, London W1T 4NJ, UK. E-mail: d.isenberg{at}ucl.ac.uk
Objectives. To assess the clinical and basic serological consequences of B-cell depletion with rituximab in the treatment of patients with systemic lupus erythematosus (SLE) who have failed conventional immunosuppression.
Methods. An open study of 24 patients with severe SLE followed for a minimum of 3 months is reported. In the majority of patients (19 out of 24), 6 months follow-up data are described. Disease activity in these patients was assessed every 1–2 months using the British Isles Lupus Assessment Group (BILAG) system and estimates of anti-double-stranded DNA antibodies and serum C3 levels. During the follow-up period, significant side-effects were sought and the reduction in oral prednisolone was recorded. It was our general practice to stop concomitant immunosuppression (e.g. azathioprine, mycophenolate) when B-cell depletion was given (in most cases in the form of two 1 g intravenous infusions of rituximab 2 weeks apart accompanied by two 750 mg intravenous cyclophosphamide infusions and two methylprednisolone infusions of 250 mg each).
Results. Twenty-two patients were female and two male. At the time of B-cell depletion, the mean age was 28.9 yr (range 17–49) and the mean disease duration was 7.9 yr (range 1–18). The global BILAG score (P < 0.00001), serum C3 (P < 0.0005) and double-stranded DNA binding (P < 0.002) all improved from the time of B-cell depletion to 6 months after this treatment. Only one patient failed to achieve B-lymphocyte depletion in the peripheral blood. The period of B-lymphocyte depletion ranged from 3 to 8 months except for one patient who remains depleted at more than 4 yr. Analysis of the regular BILAG assessments showed that improvements occurred in each of the eight organs or systems. The mean daily prednisolone dose fell from 13.8 mg (S.D. 11.3) to 10 mg (S.D. 3.1).
Conclusion. In this open study of patients who had failed conventional immunosuppressive therapy, considerable utility in the use of B-cell depletion has been demonstrated. Our data provide strong support for the performance of a full double-blind control trial.
KEY WORDS: SLE, Rituximab, B-cell depletion
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E. K. Li, L.-S. Tam, T. Y. Zhu, M. Li, C. L. Kwok, T. K. Li, Y. Y. Leung, K. C. Wong, and C. C. Szeto Is combination rituximab with cyclophosphamide better than rituximab alone in the treatment of lupus nephritis? Rheumatology, August 1, 2009; 48(8): 892 - 898. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Y. Karim, C. N. Pisoni, and M. A. Khamashta Update on immunotherapy for systemic lupus erythematosus--what's hot and what's not! Rheumatology, April 1, 2009; 48(4): 332 - 341. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Mietzner, M. Tsuiji, J. Scheid, K. Velinzon, T. Tiller, K. Abraham, J. B. Gonzalez, V. Pascual, D. Stichweh, H. Wardemann, et al. Autoreactive IgG memory antibodies in patients with systemic lupus erythematosus arise from nonreactive and polyreactive precursors PNAS, July 15, 2008; 105(28): 9727 - 9732. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Isenberg Treating patients with lupus with B-cell depletion Lupus, May 1, 2008; 17(5): 400 - 404. [Abstract] [PDF]
|
|
|
|
 |
|
 A Podolskaya, M Stadermann, C Pilkington, S D Marks, and K Tullus B cell depletion therapy for 19 patients with refractory systemic lupus erythematosus Arch. Dis. Child., May 1, 2008; 93(5): 401 - 406. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Zack and D. Isenberg Therapeutic potential (1) Lupus, March 1, 2008; 17(3): 259 - 261. [PDF]
|
|
|
|
|
|
S. J. Bowman, N. Sutcliffe, D. A. Isenberg, F. Goldblatt, M. Adler, E. Price, A. Canavan, J. Hamburger, A. Richards, S. Rauz, et al. Sjogren's Systemic Clinical Activity Index (SCAI) a systemic disease activity measure for use in clinical trials in primary Sjogren's syndrome Rheumatology, December 1, 2007; 46(12): 1845 - 1851. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Waite and E. Morrison Letter To the Editor: Severe gastrointestinal involvement in systemic lupus erythematosus treated with rituximab and cyclophosphamide (B-cell depletion therapy) Lupus, October 1, 2007; 16(10): 841 - 842. [PDF]
|
|
|
|
|
|
L. Dunkley, M. Green, and A. Gough Comment on: A case of Raynaud's phenomenon in mixed connective tissue disease responding to Rituximab therapy Rheumatology, October 1, 2007; 46(10): 1628 - 1629. [Full Text] [PDF]
|
|
|
|
 |
|
 K. P Ng, G. Cambridge, M. J Leandro, J. C W Edwards, M. Ehrenstein, and D. A Isenberg B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response Ann Rheum Dis, September 1, 2007; 66(9): 1259 - 1262. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. MacDermott, A. Adams, and T. Lehman Review: Systemic lupus erythematosus in children: current and emerging therapies Lupus, August 1, 2007; 16(8): 677 - 683. [Abstract] [PDF]
|
|
|
|
|
|
B. Ranchin and S. Fargue Review: New treatment strategies for proliferative lupus nephritis: keep children in mind! Lupus, August 1, 2007; 16(8): 684 - 691. [Abstract] [PDF]
|
|
|
|
|
|
M. Tokunaga, K. Saito, D. Kawabata, Y. Imura, T. Fujii, S. Nakayamada, S. Tsujimura, M. Nawata, S. Iwata, T. Azuma, et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system Ann Rheum Dis, April 1, 2007; 66(4): 470 - 475. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Haroon, D. O'Gradaigh, and D. Foley-Nolan A case of Raynaud's phenomenon in mixed connective tissue disease responding to rituximab therapy Rheumatology, April 1, 2007; 46(4): 718 - 719. [Full Text] [PDF]
|
|
|
|
|
|
M Schneider Exploring new territory: considering the future Lupus, March 1, 2007; 16(3): 221 - 226. [Abstract] [PDF]
|
|
|
|
|
|
M Haubitz Exploring new territory: the move towards individualised treatment Lupus, March 1, 2007; 16(3): 227 - 231. [Abstract] [PDF]
|
|
|
|
 |
|
 D. M. Arnold, F. Dentali, M. A. Crowther, R. M. Meyer, R. J. Cook, C. Sigouin, G. A. Fraser, W. Lim, and J. G. Kelton Systematic Review: Efficacy and Safety of Rituximab for Adults with Idiopathic Thrombocytopenic Purpura Ann Intern Med, January 2, 2007; 146(1): 25 - 33. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. P. Carroll, F. Brown, and P. G. Kerr Anti-CD20 antibody treatment in refractory Class IV lupus nephritis Nephrol. Dial. Transplant., January 1, 2007; 22(1): 291 - 293. [Full Text] [PDF]
|
|
|
|
|
|
A. P. Risselada and C. G. M. Kallenberg Therapy-resistent lupus skin disease successfully treated with rituximab Rheumatology, July 1, 2006; 45(7): 915 - 916. [Full Text] [PDF]
|
|
|
|
|
|
S. H. Jacobson, R. van Vollenhoven, and I. Gunnarsson Rituximab-induced long-term remission of membranous lupus nephritis Nephrol. Dial. Transplant., June 1, 2006; 21(6): 1742 - 1743. [Full Text] [PDF]
|
|